NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine - https://archive.org/web/.

And another Cancer Society leader criticizes ASCO news coverage

Posted By

Tags

Dr. Len Lichtenfeld of the American Cancer Society joins his colleague, Dr. Otis Brawley, in writing about his concerns about news coverage of the big American Society of Clinical Oncology meeting. Lichtenfeld cites a specific example, and drills down in more detail:
lichtenfeld_len.gif

“Most of the media hypes the study which demonstrated improvement in treatment of advanced ovarian cancer with a targeted therapy drug and ignore the concerns. What appeared to be a very positive study in an abstract may not have been so positive after all.

Patients, families and their physicians are now under the impression that a new advance has been made in this deadly disease, when that may not be the case. The positive press releases and news conferences were not balanced. Most of the media ignored the expert who raised legitimate concerns and cautions. But that information was only available to those who waited for the study to be presented and were in the audience at the time.

Hopes have been falsely raised, when some caution is needed and appropriate.

More importantly, patients, families and friends are going to be wondering how a study that received such a positive response in the press could possibly not be the hope they had been waiting for, and had learned about through the media reports.

Sometimes, it all comes down to getting the right understanding of what a research study really says and how that relates to its true impact. And sometimes it’s the story behind the story that you don’t see addressed in enthusiastic media reports, as is the case with this particular trial.

My sense of this particular trial is “stay tuned.” There is surely going to be more discussion of this study in the months and years ahead.

And always remember that hope sells. Tempered hope doesn’t. Failure of hope rarely gets reported. That would be (unfortunately) too brutally honest.

Sometimes, it is as simple as that.”

It is so important that these ACS officials are speaking up and writing about these issues. For many years, you would not have heard such comments from anyone at the ACS. But Brawley and Lichtenfeld are seeing things through the same prism that we see things through every day in our review of health news coverage – some excellent, but far too many unacceptably naive, fawning, cheerleading “churnalism” that may do more harm than good.

That’s what news organizations need to grasp: there can be harm caused by superficial reporting – as both Brawley and Lichtenfeld adroitly point out.

You might also like

Comments

Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.

rhana bazzini

June 9, 2010 at 3:34 pm

My oh, my, what a Pandora’s box we open with this topic!
It’s definitely a “devil is in the details” moment. Who gets financing for what studies and how are those studies conducted. Medicine, especially anything connected with cancer,is the new “sexy” topic.
Anyone who can separate the popular from the deserving has earned a Nobel.
I blame not the participants, MDs, patients, techs, etc., I fear it’s the system that has been corrupted.
Good night and good luck as ERM would say. ( a test for how old anyone who read this is :-)

@Drsteventucker

June 10, 2010 at 12:18 am

Both reports from Dr’s Brawley & Lichtenfeld are “spot on”. And similar to Rhana (above) I do not blame the doctors, scientists, or even the media teams at academic centers and industry. The blame squarely falls on the press, the media. They certainly do not seem to question their sources. Do the media teams at BP get a similar pass? How about the media reports from Fannie and Freddie or Goldman?
The goal of most of these companies is to satisfy their shareholders and to create value in the medical marketplace. They can spin the report any way they want but it is up to the reporters (and the publishers) to question such releases and summaries.
I was always taught their were only 3 goals in clinical research. Live longer, liver better, or save money. Perhaps reporters and publishers should stick to simple questions.